A SMART Design for Attendance-based Prize CM

NCT00840151 | Completed

• 2 other identifiers: 09-053-2P50DA009241-16
• Study Type: interventional
• Target: 360
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to compare different forms of treatment for substance abuse. This study will involve a type of treatment called contingency management, in which patients receive incentives (prizes) for attending outpatient treatment. This study will compare contingency management to standard treatment that does not involve incentives. This study will also compare contingency management treatment that lasts 6 weeks to contingency management that lasts 12 weeks. Finally, this study will compare contingency management treatment delivered at the beginning of outpatient treatment to contingency management treatment delivered later during outpatient treatment. The investigators hypothesize that (1) a 12-week attendance-based contingency management intervention will improve retention and enhance drug abstinence versus standard treatment, (2) initial short-term exposure to attendance-based contingency management (in weeks 1-6 only) will improve substance abuse treatment outcomes compared to standard treatment alone, and (3) contingency management in weeks 7-12 will be particularly useful for those with sporadic attendance or continued drug use during initial stages of treatment.

Conditions

Substance Abuse

Keywords

Substance Abuse; Contingency Management

Outcome Measures

Primary Outcomes (1)

• longest duration of negative drug and alcohol samples submitted

  throughout active phase and at each follow-up assessment

Secondary Outcomes (2)

• proportions of samples testing negative for drugs and alcohol

  during active phase and at each follow-up assessment

• psychosocial functioning and HIV risk behaviors

  baseline, active phase and at each follow-up assessment

Study Arms (4)

Treatment Group A

NO INTERVENTION

Individuals randomized to Treatment Group A will receive standard treatment for study weeks 1-6.

Treatment Group B

EXPERIMENTAL

Individuals randomized to Treatment Group B will receive contingency management plus standard treatment for study weeks 1-6.

Behavioral: contingency management

Aftercare Group A

NO INTERVENTION

All participants will be re-randomized after study week 6. Those participants assigned to Aftercare Group A will receive standard treatment for study weeks 7-12.

Aftercare Group B

EXPERIMENTAL

All participants will be re-randomized after study week 6. Those participants assigned to Aftercare Group B will receive contingency management treatment plus standard treatment for weeks 7-12.

Behavioral: contingency management

Interventions

contingency management BEHAVIORAL

Participants randomized to a contingency management treatment condition can earn the chance to win prizes for attending substance abuse treatment.

Aftercare Group B; Treatment Group B

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• age \> 18 years
• current DSM-IV diagnosis of cocaine abuse or dependence or recent cocaine use (self-reported use in past 30 days or positive urine toxicology screen)
• willing to sign informed consent and able to pass an informed consent quiz

You may not qualify if:

• serious, uncontrolled psychiatric illness (e.g., acute schizophrenia, bipolar disorder, severe or psychotic major depression, or suicide risk) on the basis of history or medical examination
• in recovery from pathological gambling (meet DSM-IV criteria for lifetime pathological gambling and are actively trying to refrain from gambling)
• do not speak English (all treatment is provided in English at these clinics)

Sponsors & Collaborators

• UConn Health: lead
• National Institute on Drug Abuse (NIDA): collaborator

Study Sites (1)

University of Connecticut Health Center

Farmington, Connecticut, 06030, United States

Location

MeSH Terms

Conditions

Substance-Related Disorders

Condition Hierarchy (Ancestors)

Chemically-Induced Disorders; Mental Disorders

Study Officials

• Nancy M Petry, Ph.D.

  UConn Health

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: FACTORIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 7, 2009
• First Posted: February 10, 2009
• Study Start: January 1, 2009
• Primary Completion: August 1, 2014
• Study Completion: August 1, 2014
• Last Updated: April 9, 2019

Record last verified: 2019-04

Locations

US (1)